Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01954030
Title Phase 1/2 CTO + Bevacizumab for Recurrent Glioma Post-Bevacizumab Failure
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Annick Desjardins
Indications

high grade glioma

Therapies

Bevacizumab

Carboxyamidotriazole Orotate

Age Groups: adult
Covered Countries USA


No variant requirements are available.